Dimetamfetamine

Dimetamfetamine

SCHEMBL727641

CC(Cc1ccccc1)N(C)C

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.67
SLC6A2 P23975 3/20 0.67
ADRA2B P18089 2/20 0.67
ADRA2C P18825 2/20 0.67
ADRA1A P35348 2/20 0.67
OPRK1 P41145 2/20 0.67
SLC6A3 Q01959 2/20 0.67
HTR2A P28223 1/20 0.67
KCNH2 Q12809 1/20 0.67
MAOB P27338 6/20 0.63
SIGMAR1 Q99720 5/20 0.62
MAOA P21397 5/20 0.58
CYP1A2 P05177 2/20 0.58
ADRA2A P08913 1/20 0.58
SNCA P37840 1/20 0.58
CYP2D6 P10635 1/20 0.58
PKM P14618 1/20 0.58
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.56
KDM4E B2RXH2 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimetamfetamine SCHEMBL12203605 1.00 SLC6A4 (0.67) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL2110135 1.00 SLC6A4 (0.67) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL5091346 0.98 SLC6A4 (0.64) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL11773332 0.98 SLC6A4 (0.64) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL5088134 0.98 SLC6A4 (0.64) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL28689942 0.98 SLC6A4 (0.64) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL5091391 0.98 SLC6A4 (0.64) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL30559567 0.98 SLC6A4 (0.64) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
SCHEMBL19285766 0.91 MAOB (0.69) SLC6A4SLC6A2ADRA2BADRA2CADRA1A
Dimetamfetamine SCHEMBL1240177 0.87 SLC6A4 (0.53) SLC6A4SLC6A2ADRA2BADRA2CADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-20250113829-A1 HIGH MOLECULAR WEIGHT MODIFIED RNA COMPOSITIONS nanoSUR LLC 2025-04-10 US claimed
US-12252632-B2 Chemical-mechanical polishing composition, rinse composition, chemical- mechanical polishing method, and rinsing method ENTEGRIS, INC. (US) 2025-03-18 US claimed
CN-110084368-B System and method for regularizing neural networks 谷歌有限责任公司 2025-01-28 CN claimed
CN-117078405-A Financial fraud detection method, apparatus, device and medium 中国工商银行股份有限公司 2023-11-17 CN claimed
US-20220372329-A1 CHEMICAL-MECHANICAL POLISHING COMPOSITION, RINSE COMPOSITION, CHEMICAL-MECHANICAL POLISHING METHOD, AND RINSING METHOD ENTEGRIS, INC. 2022-11-24 US claimed
US-11436496-B2 Systems and methods for regularizing neural networks GOOGLE LLC (US) 2022-09-06 US claimed
US-20200060997-A1 TARR Receptor Agonists for Sexual Dysfunction JOHN MCCOY 2020-02-27 US claimed
US-20160000815-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CT HOLDINGS PTY LTD (AU) 2016-01-07 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20100172916-A1 SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2010-07-08 US claimed
WO-2010054286-A2 SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-14 WO claimed
WO-2010015029-A1 COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) 2010-02-11 WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2006099274-A1 DIETARY SUPPLEMENT AND METHOD OF USING SAME WHEAT JARED (US) 2006-09-21 WO claimed
US-20060204599-A1 Dietary supplement and method of using same WHEAT JARED R 2006-09-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250113829-A1 HIGH MOLECULAR WEIGHT MODIFIED RNA COMPOSITIONS NSUN2, NSUN3, RNGTT SLC6A4 4839/4885SLC6A2 4876/4885ADRA2B 4672/4885
US-20100172916-A1 SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS MC1R, TYR, MITF SLC6A4 93/4885SLC6A2 98/4885ADRA2B 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.